Skip to main content

Insulin Glargine/Lixisenatide: A Review in Type 2 Diabetes

Abstract

Subcutaneous insulin glargine/lixisenatide (Suliqua™) is a titratable, fixed-ratio combination of a long-acting basal insulin analogue and a glucagon-like peptide-1 (GLP-1) receptor agonist for the treatment of adult patients with inadequately controlled type 2 diabetes. Once-daily insulin glargine/lixisenatide, in combination with metformin, provided effective glycaemic control and was generally well tolerated in the 30-week, multinational, phase 3 LixiLan-O and LixiLan-L trials in insulin-naive and -experienced adult patients with inadequately controlled type 2 diabetes. Although long-term clinical experience with this fixed-ratio combination is currently lacking, given its convenient once-daily regimen and beneficial effects on glycaemic control and bodyweight loss in the absence of an increase in the incidence of hypoglycaemia, insulin glargine/lixisenatide is an emerging option for the treatment of adult patients with type 2 diabetes to improve glycaemic control when this has not been provided by metformin alone or metformin combined with another OAD or basal insulin.

This is a preview of subscription content, access via your institution.

References

  1. International Diabetes Federation. Diabetes and cardiovascular disease: executive summary. 2016. http://www.idf.org/cvd. Accessed 9 Mar 2017.

  2. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2012;35(Suppl 1):S64–71.

    Article  Google Scholar 

  3. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centered approach. Update to position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38:140–9.

    Article  PubMed  Google Scholar 

  4. National Institute for Health and Care Excellence. Type 2 diabetes in adults: management. 2016. http://www.nice.org.uk/guidance/ng28. Accessed 9 Mar 2017.

  5. Milligan S. Combination therapy for improvement of long-term macrovascular and microvascular outcomes in type 2 diabetes: rationale and evidence for early initiation. J Diabetes Complicat. 2016;30:1177–85.

    Article  PubMed  Google Scholar 

  6. Wilding JPH, Bain SC. Role of incretin-based therapies and sodium-glucose co-transporter-2 inhibitors as adjuncts to insulin therapy in type 2 diabetes, with special reference to IDegLira. Diabet Med. 2016;33(7):864–76.

    CAS  Article  PubMed  Google Scholar 

  7. Nauck M. Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Diabet Obes Metabol. 2016;18(3):203–16.

    CAS  Article  Google Scholar 

  8. Anderson SL, Trujillo JM. Lixisenatide in type 2 diabetes: latest evidence and clinical usefulness. Ther Adv Chronic Dis. 2016;7(1):4–17.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  9. Eng C, Kramer CK, Zinman B, et al. Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis. Lancet. 2014;384:2228–34.

    CAS  Article  Google Scholar 

  10. European Medicines Agency. Suliqua 100 units/mL + 50 micrograms/mL solution in a prefilled pen, Suliqua 100 units/mL + 33 micrograms/mL solution in a prefilled pen: summary of product characteristics. 2017. http://www.ema.europa.eu. Accessed 8 Mar 2017.

  11. Sanofi-aventis US LLC. Soliqua™ 100/33 (insulin glargine and lixisenatide injection), for subcutaneous use: US prescribing information. 2016. http://www.fda.gov/. Accessed 14 Mar 2017.

  12. Blair H, Keating GM. Insulin glargine 300 U/mL: a review in diabetes mellitus. Drugs. 2016;76:363–74.

    CAS  Article  PubMed  Google Scholar 

  13. Dunn CJ, Plosker GL, Keating GM, et al. Insulin glargine: an updated review of its use in the management of diabetes mellitus. Drugs. 2003;63(16):1743–78.

    CAS  Article  PubMed  Google Scholar 

  14. Scott LJ. Lixisenatide: a review of its use in patients with type 2 diabetes mellitus. BioDrugs. 2013;27(5):509–23.

    CAS  Article  PubMed  Google Scholar 

  15. Lorenz M, Pfeffer C, Steinsträßer A, et al. Effects of lixisenatide once daily on gastric emptying in type 2 diabetes: relationship to postprandial glycemia. Regul Pept. 2013;185:1–8.

    CAS  Article  PubMed  Google Scholar 

  16. Meier JJ, Menge B, Schenker N, et al. Mechanisms of action of the glucose-lowering effect of lixisenatide in combination with insulin glargine [abstract no. 281-OR]. Diabetes. 2015;64(Suppl 1):A74.

    Google Scholar 

  17. Kovatchev B, Umpierrez G, Renard E. The differential and combined action of insulin glargine and lixisenatide on the fasting and post-prandial components of glucose control [abstract no. 3]. Diabetologia. 2016;59(Suppl 1):S2.

    Google Scholar 

  18. Rosenstock J, Aronson R, Grunberger G, et al. Benefits of LixiLan, a titratable fixed-ratio combination of insulin glargine plus lixisenatide, versus insulin glargine and lixisenatide monocomponents in type 2 diabetes inadequately controlled on oral agents: the LixiLan-O randomized trial. Diabetes Care. 2016;39(11):2026–35.

    Article  PubMed  Google Scholar 

  19. Rosenstock J, Diamant M, Aroda VR, et al. Efficacy and safety of LixiLan, a titratable fixed-ratio combination of lixisenatide and insulin glargine, versus insulin glargine in type 2 diabetes inadequately controlled on metformin monotherapy: the LixiLan proof-of-concept randomized trial. Diabetes Care. 2016;39(9):1579–86.

    Article  PubMed  Google Scholar 

  20. Davies M, Russell-Jones D, Barber TM, et al. iGlarLixi fixed-ratio combination in patients with HbA1c ≥9%: LixiLan-O subgroup analysis [abstract]. 2017. In: 77th ADA Meeting; 2017.

  21. Handelsman Y, Chovanes C, Dex T, et al. Efficacy and safety of insulin glargine/lixisenatide fixed-ratio combination in elderly patients with T2D [abstract no. 954-P]. Diabetes. 2016;65(Suppl 1):A246.

    Google Scholar 

  22. Davis M, Leiter LA, Grunberger G, et al. Impact of baseline HbA1c, BMI, and diabetes duration on the efficacy and safety of LixiLan (insulin glargine/lixisenatide titratable fixed-ratio combination) vs. insulin glargine and lixisenatide in the LixiLan-O trial [abstract no. 1028-P]. Diabetes. 2016;65(Suppl 1):A268.

    Google Scholar 

  23. Aroda VR, Rosenstock J, Wysham C, et al. Efficacy and safety of LixiLan, a titratable fixed-ratio combination of insulin glargine plus lixisenatide in type 2 diabetes inadequately controlled on basal insulin and metformin: the LixiLan-L randomized trial. Diabetes Care. 2016;39(11):1972–80.

    Article  PubMed  Google Scholar 

  24. Wysham C, Bonadonna RC, Aroda V, et al. Consistent findings in glycaemic control, body weight and hypoglycaemia with iGlarLixi (insulin glargine/lixisenatide titratable fixed-ratio combination) vs insulin glargine across baseline HbA1c, BMI and diabetes duration categories in the LixiLan-L trial. Diabetes Obes Metab. 2017. doi:10.1111/dom.12961.

    Google Scholar 

  25. Ritzel R, Vidal J, Aroda VR, et al. Efficacy and safety across the final dose ranges in patients with T2DM receiving insulin glargine/lixisenatide fixed-ratio combination in the LixiLan-L trial [abstract no. 1024-P]. Diabetes. 2016;65(Suppl 1):A266–7.

    Google Scholar 

  26. ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012;367(4):319–28.

    Article  Google Scholar 

  27. Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373(23):2247–57.

    CAS  Article  PubMed  Google Scholar 

  28. International Diabetes Federation. Global diabetes plan 2011-2021. 2011. http://www.idf.org. Accessed 21 Mar 2017.

  29. Levin PA. Practical combination therapy based on pathophysiology of type 2 diabetes. Diabetes Metabol Syndr Obesity Targets Ther. 2016;9:355–69.

    Article  Google Scholar 

  30. Greig SL, Scott LJ. Insulin degludec/liraglutide: a review in type 2 diabetes. Drugs. 2015;75(13):1523–34.

    CAS  Article  PubMed  Google Scholar 

  31. European Medicines Agency. Xultophy 100 units/mL + 3.6 mg/mL liraglutide solution for injection: summary of product characteristics. 2014. http://www.ema.europa.eu. Accessed 21 March 2017.

  32. Van Gaal L, Scheen A. Weight management in type 2 diabetes: current and emerging approaches to treatment. Diabetes Care. 2015;38:1161–72.

    Article  PubMed  Google Scholar 

  33. Riddle MC, Forst T, Aronson R, et al. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine. Diabetes Care. 2013;36(9):2497–503.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  34. Riddle MC, Aronson R, Home P, et al. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin. Diabetes Care. 2013;36(9):2489–96.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  35. Seino Y, Min KW, Niemoeller E, et al. Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia). Diabetes Obes Metab. 2012;14(10):910–7.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  36. Rosenstock J, Guerci B, Hanefeld M, et al. Prandial options to advance basal insulin glargine therapy: testing lixisenatide plus basal insulin versus insulin glulisine either as basal-plus or basal-bolus in type 2 diabetes: the GetGoal Duo-2 trial. Diabetes Care. 2016;39(8):1318–28.

    Article  PubMed  Google Scholar 

  37. Eto K, Naito Y, Seino Y. Evaluation of efficacy and safety of lixisentide add-on treatment to basal insulin therapy among T2DM patients with different body mass indices from GetGoal trials. Diabetol Metab Syndr. 2015;7:106.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Zannad F, Stough WG, Lipicky RJ, et al. Assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk asessment vs. risk aversion. Eur Heart J. 2016;2:200–5.

    Google Scholar 

  39. European Medicines Agency. Guidelines on clinical investiagtion of medicinal products in the treatment or prevention of diabetes mellitus. 2012. http://www.ema.europa.eu. Accessed 22 Mar 2017.

Download references

Acknowledgements

During the peer review process, the manufacturer of insulin glargine/lixisenatide was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Lesley J. Scott.

Ethics declarations

Funding

The preparation of this review was not supported by any external funding.

Conflicts of interest

Lesley Scott is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.

Additional information about this Adis Drug Review can be found at http://www.medengine.com/Redeem/1D48F060445E4DE0.

Additional information

The manuscript was reviewed by: S.C. Bain, Swansea University, Institute of Life Science, Swansea, United Kingdom; J.C. Eriksson, Department of General Practice and Primary Health Care, University of Helsinki, and Unit of General Practice, Finland and Helsinki University Central Hospital, Helsinki, Finland; N. Papanas, Democritus University of Thrace, Diabetes Care, Second Department of Internal Medicine, Alexandroupolis, Greece; J. Perez-Castrillon, Universidad de Valladolid, Institute of Endocrinology and Nutrition, Valladolid, Spain; A.J. Scheen, Division of Diabetes, Nutrition and Metabolic Disorders, Department of Medicine, CHU Liège, and Division of Clinical Pharmacology, CIRM, University of Liège, Liège, Belgium; T. Tzotzas, Agios Pavlos General Hospital, Thessaloniki, Greece.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 17.6 kb)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Scott, L.J. Insulin Glargine/Lixisenatide: A Review in Type 2 Diabetes. Drugs 77, 1353–1362 (2017). https://doi.org/10.1007/s40265-017-0783-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-017-0783-4